Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Sona Nanotech Inc. (C:SONA)

Business Focus: Medical Equipment, Supplies & Distribution (NEC)

Sector:  Healthcare Industry:  Medical Equipment, Supplies & Distribution
 
See Regulatory Filings on SEDAR
Company Contact
Address: Purdy's Wharf Tower 2
1969 Upper Water St Suite 2001
HALIFAX NS B3J 3R7
Tel: N/A
Website: https://www.sonanano.com
IR: See website
Key People
Darren Rowles
President, Chief Scientific Officer
David Andrew Regan
Chief Executive Officer
Robert Randall
Chief Financial Officer, Corporate Secretary
Business Overview
Sona Nanotech Inc. is a nanotechnology life sciences company that has developed multiple methods for manufacturing rod-shaped gold nanoparticles. The Company is engaged in the research and development of its technology for use in multiplex diagnostic testing platforms and biomedical applications. Its core technology is a rod-shaped nanoparticle manufactured at scale with surfactants that allow the production of two different product lines (Gemini and Omni) for use in both in-vitro and in-vivo applications, such as lateral flow diagnostics and cell imaging respectively. The Company's gold nanorod particles are manufactured without the use of CTAB (cetyltrimethylammonium), eliminating the toxicity risks associated with the use of other gold nanorod technologies in medical applications. The Company also offers development services to help lateral flow producers create new lateral flow tests and improve existing tests for their product iteration.
Financial Overview
For the six months ended 30 April 2022, Sona Nanotech Inc revenues was not reported. Net loss decreased 63% to C$2.5M. Lower net loss reflects Share-based compensation decrease of 66% to C$1.8M (expense), Salaries and benefits decrease of 29% to C$473K (expense), Professional and consulting fees decrease of 55% to C$146K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -C$0.11 to -C$0.04.
Employees: 8 as of Oct 31, 2021
Reporting Currency: Canadian Dollars
Enterprise value: $5.86M as of Apr 30, 2022
Annual revenue (TTM): $0.00M as of Apr 30, 2022
EBITDA (TTM): -$6.63M as of Apr 30, 2022
Net annual income (TTM): -$6.05M as of Apr 30, 2022
Free cash flow (TTM): -$3.10M as of Apr 30, 2022
Net Debt Last Fiscal Year: N/A
Shares outstanding: 68,987,904 as of Apr 30, 2022
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization